CYP2D6-Guided Opioid Management and Postoperative Pain Control: A Randomized Clinical Trial.

ABSTRACT:

Importance

Individuals with genetic variation that results in absent (poor metabolizers) or reduced (intermediate metabolizers) cytochrome P450 2D6 (CYP2D6) enzyme activity have lower concentrations of highly potent active metabolites of tramadol, hydrocodone, and codeine and are thus at increased risk for inadequate pain control.

Objective

To determine the effect of CYP2D6-guided opioid prescribing on postoperative pain and opioid use.

Design, setting, and participants

This open-label randomized clinical trial enrolled participants from surgery clinics at 8 US health systems. Individuals undergoing a planned surgery anticipated to cause postoperative pain for at least 7 to 10 days were enrolled from March 2021 to September 2023, with follow-up concluded in March 2024

SUBMITTER: Cavallari LH 

PROVIDER: S-EPMC12924106 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature